tipranavir (aptivus) Report issue

Small molecule Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tipranavir (PNU-140690, trade mark APTIVUS) is a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Tipranavir has potent in vitro activity against a variety of HIV-1 laboratory strains and clinical isolates, including those resistant to ritonavir, as well as HIV-2. The drug is launched in several countries, including the US and in the EU. APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.   NCATS

Chemistry

  • SMILES: CCC[C@@]2(CCC1=CC=CC=C1)CC(O)=C([C@H](CC)C3=CC=CC(NS(=O)(=O)C4=NC=C(C=C4)C(F)(F)F)=C3)C(=O)O2
  • InChIKey: SUJUHGSWHZTSEU-FYBSXPHGSA-N
  • Mol. Mass: 602.664
  • ALogP: 7.33
  • ChEMBL Molecule:
    tipranavir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$4.3367 - $14.7721

Australia

$4.7329
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

3'-((1r)-1-((6r)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | aptivus | pnu 140690 | pnu-140690 | tipranavir | tipranavir, (r-(r*,r*))-isomer | tipranavir, (s-(r*,r*))-isomer | tipranavir, (s-(r*,s*))-isomer | tipranivir | u-140690

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Acquired Immunodeficiency Syndrome (Phase 2/Phase 3)

Cardiovascular Diseases (Phase 4)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Hepatitis C, Chronic (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue